RxDoctor Payments Data

Michael Johnston, MD

Internal Medicine · Dallas, TXNPI 1144232265

Payments from drug & device makers

$1,031in general payments, 2019–2025

Across 60 payments — averaging $17.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$271
  • GSK$221
  • Astellas Pharma US Inc$170
  • AbbVie$95
  • Abbott$53
  • Boston Scientific$43
  • plus $179 from 9 others

What the payments were for

  • Speaking & faculty fees$202%
  • Food & beverage$1,01198%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,031 in reported general payments places this provider in the 65th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$260,614
Medicare patients
469
Services billed
5,788

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide208$255,957
FarxigaDapagliflozin Propanediol152$144,720
JardianceEmpagliflozin117$134,056
Trelegy ElliptaFluticasone/Umeclidin/Vilanter105$98,227
EliquisApixaban82$81,150
MounjaroTirzepatide36$48,166
XareltoRivaroxaban38$36,515
TrulicityDulaglutide22$36,140
JanuviaSitagliptin Phosphate29$34,473
Janumet XrSitagliptin Phos/Metformin Hcl31$32,381
Tresiba Flextouch U-200Insulin Degludec27$18,055
Breo ElliptaFluticasone/Vilanterol23$13,718
Tresiba Flextouch U-100Insulin Degludec15$10,057
Rosuvastatin Calcium653$9,329
QuviviqDaridorexant Hcl11$8,580

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$271$255,957208 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$221$117,219139 claims
Lilly USA, LLCMounjaro, Trulicity$29$84,30658 claims
MerckJanuvia, Janumet Xr$27$66,85460 claims
Johnson & JohnsonXarelto$23$36,51538 claims
AbbVieSynthroid$95$2,16045 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Dallas

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →